Drug-eluting balloons: What is their place on the interventionalist's shelf?

Heart

Volumn 96, Issue 16, 2010, Pages 1257-1258

  Banning, Adrian P ^a   Lim, Chris C S ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANGIOGRAPHY; ATHEROMA; BALLOON CATHETER; BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG ELUTING STENT; EDITORIAL; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; HUMANS; PACLITAXEL;

EID: 77955443146     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.201376     Document Type: Editorial

References (15)

1. Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation 1994;89:2888-91. (Pubitemid 24173712)
2. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. (Pubitemid 40617065)
3. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9. (Pubitemid 46376802)
4. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimuseluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78. (Pubitemid 46281313)
5. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45. (Pubitemid 27329445)
6. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003;42:1415-20. (Pubitemid 37267283)
7. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003;24:1462-7.
8. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-14. (Pubitemid 39096008)
9. Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: comparison of effectiveness of non-stentbased local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 2006;240:411-18. (Pubitemid 44098636)
10. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113-24. (Pubitemid 44749319)
11. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008;97:773-81.
12. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxelcoated stent for the treatment of coronary in-stent restenosis. Circulation 2009;119:2986-94.
13. Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2010;99:165-74.
14. Cortese B, Micheli A, Picchi A, et al. Paclitaxelcoated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomized clinical trial. The PICCOLETO Study. Heart 2010;96:1291-6.
15. Results of the DEBUIT Drug Eluting Balloon in Bifurcations Trial. Late-breaking trial presentation. EuroPCR, Paris, France 26 May 2010.